Pharmaceutical Contract Development and Manufacturing Market by Service (Drug Development Services, Biologics Manufacturing Services, and Pharmaceutical Manufacturing Services), End User (Generic Pharmaceutical Companies, Small and Mid-Size Pharmaceutical Companies, and Big Pharmaceutical Companies) and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027071 | Pages: 100 | Industry: Healthcare IT | Date: Oct 2022 | Type: Global

The market crossed the US$ 130.80 billion mark in 2022 and is expected to hit US$ 212.45 billion by 2030, recording a CAGR of 6.3% during the forecast period.

The rising prevalence of chronic diseases will result in the high adoption of pharmaceutical contract development and manufacturing services.

Chronic diseases, including heart disease, stroke, diabetes, and obesity, account for most of the healthcare costs of any country. According to a report by the World Health Organization (WHO), 463 million adults in the world had diabetes in 2020, which is expected to rise to 629 million by 2045. Moreover, per the Centers for Disease Control and Prevention (CDC) data published in 2018, 1.4 million Americans are diagnosed with diabetes yearly in the US. To enhance chronic disease management and offer more treatment options to patients, pharmaceutical contract development and manufacturing services help to deliver evidence-based therapeutic solutions. It enables patients and market players to control their care better and provides potential solutions for managing chronic diseases like diabetes.

Within the report, the market is segmented into service, end user and geography. The market is segmented by services into drug development services, biologics manufacturing services, and pharmaceutical manufacturing services. The biologics manufacturing services are further bifurcated into biologics FDF manufacturing services and biologics API manufacturing services. The pharmaceutical manufacturing services are further bifurcated into pharmaceutical FDF and API manufacturing services. Based on end user, the market is segmented into generic pharmaceutical companies, small and mid-size pharmaceutical companies, and big pharmaceutical companies. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

The drug development services segment holds the largest market share by services.

Developing drugs or APIs is referred to as pharmaceutical contract development and manufacturing services. With rising R&D and manufacturing costs, contract development and manufacturing of pharmaceutical products such as drugs have become more popular. The contract development and manufacturing company serve drug development and manufacturing services on a contract basis. CROs are specifically designed to perform these testing services to reduce the in-house cost and time of the companies required to conduct the extensive range of testing services to comply with the national and international regulatory standards. The increasing trend of contract manufacturing among numerous pharmaceutical companies is expected to propel the market growth during the forecast period.

The increasing trend of contract manufacturing among drug companies will drive the growth of the market

Key players are widely accepting pharmaceutical contract development and manufacturing services. The market is growing due to the demand by these key players to be more involved in continuous innovation and technological advances, leading to increased acceptance. Leading players invest in R&D to develop advanced technologies and gain more revenue. Moreover, the disaster of a rising number of drugs failure in the last phases of the product development cycle has cost money and valuable time invested in product engineering. This has led to higher investments in developing fresher technology for easing product engineering, thereby promoting growth in the market.               

Recent strategic developments in the pharmaceutical contract development and manufacturing market

The pharmaceutical contract development and manufacturing market have undergone several significant developments, and a few of these have been mentioned below:

  • In October 2021, Genetic Analysis AS (GA), a company that specializes in molecular diagnostics, announced a service agreement with Eurofins ADME BIOANALYSES, a Contract Research Organization (CRO) that offers the pharmaceutical industry a range of services in the areas of pharmacokinetics, pharmacodynamics, and drug metabolism
  • In June 2021, Charles River Laboratories completed the acquisition of Vigene Biosciences for US$ 292.5 million in cash. The acquisition of Vigene Biosciences’ extensive gene therapy capabilities further enhanced Charles River’s position as a premier scientific partner for cell and gene therapies.
  • In April 2021, Parexel and Veeva Systems entered a strategic collaboration to accelerate clinical trials through technology and process innovation. The association integrated the best of each company’s experience across thousands of clinical studies worldwide.

Several players drive the pharmaceutical contract development and manufacturing market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. AbbVie Inc.; Almac Group; Catalent, Inc.; Evonik; Lonza; Recipharm AB (publ); Siegfried Holding AG; Aenova Group GmbH; Vetter Pharma International GmbH; Samsung Biologics are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Service providers
  • Market-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Distributors and sales firms
  • End users of medical devices
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • By Service:
    • Drug Development Services
    • Biologics Manufacturing Services
      • Biologics FDF Manufacturing Services
      • Biologics API Manufacturing Services
    • Pharmaceutical Manufacturing Services
      • Pharmaceutical API Manufacturing Services
      • Pharmaceutical FDF Manufacturing Services
  • End User:
    • Generic Pharmaceutical Companies
    • Small and Mid-Size Pharmaceutical Companies
    • Big Pharmaceutical Companies
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • AbbVie Inc.
    • Almac Group
    • Catalent, Inc.
    • Evonik
    • Lonza
    • Recipharm AB (publ)
    • Siegfried Holding AG
    • Aenova Group GmbH
    • Vetter Pharma International GmbH
    • Samsung Biologics

The List of Companies
- AbbVie Inc.
- Almac Group
- Catalent, Inc.
- Evonik
- Lonza
- Recipharm AB (publ)
- Siegfried Holding AG
- Aenova Group GmbH
- Vetter Pharma International GmbH
- Samsung Biologics

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500